|
Opinion
Courting
controversy
Market
Moving
to a new level
An attractive growth rate and relatively lower costs are drawing
global companies to the Indian biotech industry. Indian players
have many options, but they need to upgrade their capabilities
as well. Usha Sharma does a status check
Jubilant
join hands with Lilly
Jubilant Organosys and Eli Lilly have entered into an agreement
to form an equally-owned Joint Venture (JV) in India. The
JV will focus on providing drug development services exclusively
to Jubilant and Lilly-partnered molecules
Piramal
gets Canadian nod for phase I trial of cancer molecule
Piramal Life Sciences (PLS) has received regulatory approval
in Canada for the initiation of a phase I study of a new cancer
compound, P-1446A-05
BSV
inks an in licensing deal with Actavis
Bharat Serums and Vaccines (BSV) has entered into an exclusive
licensing, manufacturing and supply agreement with Actavis
for marketing of one of BSV's anti-infective generic formulations
Natco
launches nanotechnology cancer drug in India
Natco Pharma has introduced its first nanotechnology drug,
'Albupax' in the domestic market. Currently, Albupax is available
in some parts of country but soon it will have pan India availability
Arbro
inks pact with JNU professor for anthrax vaccine
Arbro Pharmaceuticals, has joined hands with Professor Rakesh
Bhatnagar, Jawaharlal Nehru University (JNU), Delhi for developing
an effective regime to neutralise effects of anthrax
Not
a big affair
Biotech Hub India 2008 was not a big affair, with students
comprising a majority of the audience. However the topics
discussed showcased the myriad opportunities open to India
in different segments of biotechnology. Arshiya Khan reports
CREMA
conference on challenges of patient recruitment and retention
Clinical research organisations (CROs) in the country are
facing a huge issue of lack of availability of right kind
of patients for clinical trials
Management
Controversy's
child
Safety and quality issues have always dogged the vaccine sector,
and when the National Regulatory Authority was recently de-recognised
by the World Health Organisation, it took down the reputation
of domestic vaccine players with it. Aashruti Kak reviews
past and present vaccine controversies
Going
strong
Lantus, the leading brand in the basal insulin segment, recently
bagged the Organisation of Pharmaceutical Producers of India’s
(OPPI) Marketing Excellence Award in the Existing Product
category. This only goes to prove that Lantus combines sound
bramd management with superior patient care. Suja Nair speaks
to Susheel Umesh, Senior Director, Cardio-Metabolism Business
Unit, Aventis Pharma (Group Sanofi-Aventis) about their winning
product and marketing strategies
Technology
A
fine balance
In spite of offering many advantages over synthetic hormones,
bio-identical hormone replacement therapy (BIHRT) finds few
takers. Suja Nair finds out why
Mesenchymal
stem cells might be the answer to spinal cord injury
In India, 20,000 new cases of spinal cord injury are added
to the list every year, as compared to 11,000 in US and 700
in UK. Stempeutics Research has done a pilot study on the
application of mesenchymal stem cells in spinal cord injury
Beckman
Coulter cell culture flask adapters
During various stages of the cell culturing process, centrifugation
is frequently used to isolate extracellular products or to
separate cells from their aqueous environment
|
